Comments
Suven Life Sciences Ltd has secured three patents, one each from Israel, Japan and South Africa, corresponding to its New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven which are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders such as Alzheimer’s disease, attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinsons, and Schizophrenia, the Hyderabad-based company said in a release issued here on Tuesday.
With these new patents, Suven has a total of six patents from Israel, 17 from Japan and 20 from South Africa. ``These granted patents are the exclusive intellectual property of Suven and are achieved through internal discovery research efforts. Products of these inventions may be out-licensed at various phases of clinical development such as at Phase-I or Phase-II,’’ the company said.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.